Hvivo, the pharmaceutical services company formerly known as Open Orphan, said revenue rose last year and raised its medium term targets to £100 million in revenue by 2028. In a

Irish pharma firms took in $1.5 billion across seven deals last year, led higher by the sale of Cathal Friel’s Amryt Pharma The value of merger and acquisition (M&A) transactions

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge

Pharmaceutical services firm Hvivo has signed a £6.3m (€7.3m) contract with a biotechnology client. Irish-founded Hvivo runs drug trials known as challenge studies from its London clinics. The company will

Hvivo, the pharmaceutical services company formerly known as Open Orphan, has signed a contract worth £6.3 million (€7.3 million) to test a potential treatment for the common cold. The contract,